Gordon Ariel 13D and 13G filings for NeuroSense Therapeutics Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 1:20 pm Purchase | 2023-12-31 | 13G | NeuroSense Therapeutics Ltd. NRSN | Gordon Ariel | 1,060,561 6.900% | 7,674 (+0.73%) | Filing |
| 2023-03-15 3:42 pm Purchase | 2022-12-31 | 13G | NeuroSense Therapeutics Ltd. NRSN | Gordon Ariel | 1,052,887 8.920% | 15,480 (+1.49%) | Filing |
| 2021-12-20 4:40 pm Purchase | 2021-12-13 | 13G | NeuroSense Therapeutics Ltd. NRSN | Gordon Ariel | 1,037,407 9.480% | 1,037,407 (New Position) | Filing |